AllSight
Companies · LBRX · Pharmaceutical Preparations

LB PHARMACEUTICALS INC (LBRX)

LB PHARMACEUTICALS INC (LBRX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

LB PHARMACEUTICALS INC (LBRX) stock — financials & valuation

Key numbers for LB PHARMACEUTICALS INC (LBRX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 45/100 — a percentile rank of LB PHARMACEUTICALS INC’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.

Market cap$1.2B
EV / EBITDA-9.7×
Return on equity-25.8%
ROIC-193.2%
Debt / equity0.0×
Dividend yield0.0%

Independent of the events above — derived from LB PHARMACEUTICALS INC’s own financial statements and shown as context, never as advice.

Sep 15, 2026CMO appointment
LB Pharmaceuticals names seasoned CNS CMO as LB-102 pipeline enters late-stage execution
Sep 3, 2026CFO appointment
LB Pharmaceuticals names seasoned CFO as finance leadership rebuild continues
Aug 11, 2026
Phase 3 readout moves into H1 2027, but the update is largely known
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact